EcoDrugPlus

Guanylate Cyclase 1 Soluble Subunit Alpha 1

Ensembl ID : ENSSAUG00010015168
Gene Symbol: GUCY1A1
3 Cross references
201 Possible Orthologues:

Guanylate Cyclase 1 Soluble Subunit Alpha 2

Ensembl ID : ENSSAUG00010000180
Gene Symbol: GUCY1A2
3 Cross references
202 Possible Orthologues:

Guanylate Cyclase 1 Soluble Subunit Beta 1

Ensembl ID : ENSSAUG00010015185
Gene Symbol: GUCY1B1
1 Cross references
210 Possible Orthologues:

Heat Shock Protein 90 Alpha Family Class B Member 1

Ensembl ID : ENSSAUG00010005268
Gene Symbol: HSP90AB1
3 Cross references
339 Possible Orthologues:

Heat Shock Protein Hsp 90-Alpha

Ensembl ID : ENSSAUG00010025665
Gene Symbol: LOC115574290
3 Cross references
345 Possible Orthologues:

High Mobility Group Protein B1-Like

Ensembl ID : ENSSAUG00010023364
Gene Symbol: LOC115568768
3 Cross references
509 Possible Orthologues:

High Mobility Group-T Protein-Like

Ensembl ID : ENSSAUG00010024903
Gene Symbol: LOC115594324
2 Cross references
511 Possible Orthologues:

Histamine Receptor H1

Ensembl ID : ENSSAUG00010013292
Gene Symbol: HRH1
3 Cross references
186 Possible Orthologues:

Histamine Receptor H2

Ensembl ID : ENSSAUG00010002644
Gene Symbol: HRH2
1 Cross references
182 Possible Orthologues:

Histamine Receptor H2a

Ensembl ID : ENSSAUG00010006811
Gene Symbol: HRH2A
1 Cross references
189 Possible Orthologues:

Histone Deacetylase 10

Ensembl ID : ENSSAUG00010026471
Gene Symbol: HDAC10
3 Cross references
181 Possible Orthologues:

Histone Deacetylase 11

Ensembl ID : ENSSAUG00010018072
Gene Symbol: HDAC11
3 Cross references
202 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).